Cost-Effectiveness of Polygenic Risk Scores to Guide Statin Therapy for Cardiovascular Disease Prevention.

Michel KiflenAnn LeShihong MaoRicky LaliSukrit NarulaFeng Xie Guillaume Paré

Published in: Circulation. Genomic and precision medicine (2022)

This study suggests that using PRS alongside existing guidelines might be cost-effective for CVD. Stronger predictiveness combined with decreased cost of PRS could further improve cost-effectiveness, providing an economic basis for its inclusion into clinical care.

Keyphrases

cardiovascular disease
healthcare
palliative care
type diabetes
coronary artery disease
clinical practice
quality improvement
cardiovascular events
low density lipoprotein